Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious technique, conolidine modulates alternate molecular targets. A Science Advances review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://brado466hby5.tokka-blog.com/profile